SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study) is a research paper published in Clinical Lung Cancer (2020). On theSindex it has a DataRank of 0. It has been cited 11 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NCI NIH HHS
Grant: UG1 CA189971
NCI NIH HHS
Grant: UG1 CA189873
NCI NIH HHS
Grant: U10 CA142559
NCI NIH HHS
Grant: N01 CA013612
NCI NIH HHS
Grant: UM1 CA186704
NCI NIH HHS
Grant: UG1 CA189854
NCI NIH HHS
Grant: UG1 CA189972
NCI NIH HHS
Grant: UG1 CA233340
NCI NIH HHS
Grant: U10 CA180820
NCI NIH HHS
Grant: U10 CA046368
NCI NIH HHS
Grant: U10 CA180888
NCI NIH HHS
Grant: U10 CA180868
NCI NIH HHS
Grant: U10 CA180826
NCI NIH HHS
Grant: UG1 CA189804
NCI NIH HHS
Grant: P30 CA093373
NCI NIH HHS
Grant: UG1 CA233329
NCI NIH HHS
Grant: UG1 CA189821
NCI NIH HHS
Grant: U10 CA013612
NCI NIH HHS
Grant: U10 CA180835
NCI NIH HHS
Grant: UG1 CA233330
NCI NIH HHS
Grant: U10 CA180821
NCI NIH HHS
Grant: U10 CA180801
NCI NIH HHS
Grant: U10 CA180858
NCI NIH HHS
Grant: UG1 CA189822
NCI NIH HHS
Grant: UG1 CA189952
NCI NIH HHS
Grant: U10 CA180846
NCI NIH HHS
Grant: UG1 CA189858
NCI NIH HHS
Grant: UG1 CA189860
NCI NIH HHS
Grant: UG1 CA189830
NCI NIH HHS
Grant: UG1 CA189954
NCI NIH HHS
Grant: U10 CA011083
NCI NIH HHS
Grant: UG1 CA189808
NCI NIH HHS
Grant: U10 CA180819
NCI NIH HHS
Grant: UG1 CA189953
NCI NIH HHS
Grant: P30 CA006927
FWCI
0.30
Citation Percentile
0.6%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals